⌕
PTC Therapeutics · PTCT · Nasdaq
Tenet 57 · Mixed
Compare
$60.97−3.97%At closeTenet 57 · Mixed
$60.97−2.52 (−3.97%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

PTC Therapeutics (PTCT) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● MarketBeatNov 16, 2026 · 19:17 ETEARNINGS EXPECTED BY FEB 25
PTC Therapeutics Sees $2 Billion-Plus Sephience Potential, Sets January Guidance Date

PTC Therapeutics NASDAQ: PTCT expects to provide 2027 sales guidance for its oral phenylketonuria treatment Sephience in January, as executives seek to convince investors that the drug's strong first year of sales can be…

● Seeking AlphaNov 3, 2026 · 11:31 ETEARNINGS EXPECTED BY FEB 25
PTC Therapeutics: Sephience Keeps Beating The Forecast, But The Price Already Knows

PTC Therapeutics (PTCT) is rated Hold, bordering on Sell, with fair value estimated at $52/share versus a $59.97 current price. Sephience's strong launch drives growth, but legacy product declines offset gains; Q4 and 20…

● PRNewsWireNov 3, 2026 · 07:00 ETCOMPANY'S OWN WORDS
PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program

WARREN, N.J., Nov. 3, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that its Board of Directors has authorized a share repurchase program under which PTC may repurchase up to $500 million of…

● PRNewsWireNov 2, 2026 · 08:00 ETCOMPANY'S OWN WORDS
PTC Therapeutics to Participate in Upcoming Investor Conferences

WARREN, N.J., Nov. 2, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Jefferies Global Healthcare Conference  Monday, Nov. 16 at 11 …

● PRNewsWireOct 30, 2026 · 16:30 ETCOMPANY'S OWN WORDS
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WARREN, N.J., Oct. 30, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Oct. 28, 2026, the company approved non-statutory stock options to purchase an aggregate of 9.620 shares of its co…

● Seeking AlphaOct 29, 2026 · 23:08 ETEARNINGS EXPECTED BY FEB 25
PTC Therapeutics, Inc. (PTCT) Q3 2026 Earnings Call Transcript

PTC Therapeutics, Inc. (PTCT) Q3 2026 Earnings Call Transcript…

● MarketBeatOct 29, 2026 · 21:15 ETEARNINGS EXPECTED BY FEB 25
PTC Therapeutics Q3 Earnings Call Highlights

PTC Therapeutics NASDAQ: PTCT reported third-quarter 2026 total revenue of $358 million, including $276 million in net product revenue, as sales of phenylketonuria treatment Sephience continued to expand in the United St…

● Zacks Investment ResearchOct 29, 2026 · 19:01 ETEARNINGS EXPECTED BY FEB 25
PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and t…

● Zacks Investment ResearchOct 29, 2026 · 18:36 ETEARNINGS EXPECTED BY FEB 25
PTC Therapeutics (PTCT) Q3 Earnings and Revenues Surpass Estimates

PTC Therapeutics (PTCT) came out with quarterly earnings of $0.61 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.2 per share a year ago.…

● PRNewsWireOct 29, 2026 · 16:01 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 25
PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results

– Strong Q3 2026 performance with total revenue of $358 million, including $276 million of product revenue – – Full-year 2026 expected total revenue increased to $1.29 to $1.32 billion, with full-year product revenue gui…

● Zacks Investment ResearchOct 22, 2026 · 11:01 ETEARNINGS EXPECTED BY FEB 25
Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

● Defense WorldOct 19, 2026 · 04:22 ET
PTC Therapeutics (NASDAQ:PTCT) Director Sells $149,025.00 in Stock

PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) Director Michael Schmertzler sold 2,500 shares of the stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $59.61, for a tot…

● PRNewsWireOct 15, 2026 · 08:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 25
PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026

WARREN, N.J., Oct. 15, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its third quarter 2026 financial results and provide a busi…

● Defense WorldOct 8, 2026 · 07:08 ET
PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 435 Shares of Company Stock

PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) VP Mark Boulding sold 435 shares of the company's stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $64.16, for a total t…

● Defense WorldOct 5, 2026 · 08:14 ETEARNINGS EXPECTED BY FEB 25
Comparing PTC Therapeutics (NASDAQ:PTCT) and Precigen (NASDAQ:PGEN)

Precigen (NASDAQ: PGEN - Get Free Report) and PTC Therapeutics (NASDAQ: PTCT - Get Free Report) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the st…

● Defense WorldSep 30, 2026 · 06:41 ET
PTC Therapeutics (NASDAQ:PTCT) Shares Climb 4.7% – Here’s Why

Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) shot up 4.7% during trading on Monday. The stock traded as high as $65.75 and last traded at $65.60. 659,183 shares were traded during mid-day trading, a …

● PRNewsWireSep 25, 2026 · 16:30 ETCOMPANY'S OWN WORDS
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WARREN, N.J., Sept. 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Sept.…

● PRNewsWireSep 21, 2026 · 16:30 ETEARNINGS EXPECTED BY FEB 25
PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy

– Completion of BLA submission expected in Q4 2026 – WARREN, N.J., Sept. 21, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it completed the previously announced agreement with Sangamo T…

● Seeking AlphaSep 15, 2026 · 12:51 ET
PTC Therapeutics, Inc. (PTCT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

PTC Therapeutics, Inc. (PTCT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

● Defense WorldSep 15, 2026 · 04:07 ETEARNINGS EXPECTED BY FEB 25
Amundi Raises Holdings in PTC Therapeutics, Inc. $PTCT

Amundi grew its stake in shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) by 171.7% during a recent quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The ins…

● Defense WorldSep 15, 2026 · 03:26 ETEARNINGS EXPECTED BY FEB 25
California State Teachers Retirement System Has $543.82 Million Stock Position in PTC Therapeutics, Inc. $PTCT

California State Teachers Retirement System raised its stake in shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) by 7,806.7% during a recent quarter, according to the company in its most recent Form 13F filing with the Se…

● PRNewsWireAug 27, 2026 · 08:00 ETCOMPANY'S OWN WORDS
PTC Therapeutics to Participate in Upcoming Investor Conferences

WARREN, N.J., Aug. 27, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Wells Fargo 21st Annual Healthcare Conference Thursday, Sept.…

● PRNewsWireAug 24, 2026 · 08:00 ETCOMPANY'S OWN WORDS
PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile

– 17 abstracts and presentations planned at SSIEM Symposium – – Real-world evidence demonstrates significant diet liberalization achieved with Sephience while maintaining target blood Phe levels – – Continued evidence of…

● Seeking AlphaAug 24, 2026 · 05:31 ET
PTC Therapeutics: An Acquisition Which Could Unlock Massive Potential

PTC Therapeutics offers a compelling risk-reward profile, with its valuation not fully reflecting the upside from Sephience and potential ST-920 approval. Sephience, PTCT's lead asset, has driven rapid revenue growth, ac…

● MarketBeatAug 16, 2026 · 11:02 ET
PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal

PTC Therapeutics NASDAQ: PTCT plans to acquire the ST-920 Fabry disease gene therapy asset through a competitive bankruptcy auction, positioning the company to add a potential one-time treatment to its rare disease portf…

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 25. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

Quiet tape today.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.